Elan

Elan FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Elan (6099.T) as of Oct 9, 2026 is 114.83 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 153.90 % — a change of -25.38% (lower).

FCF Conversion

114.83 %

YoY

-25.38%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Elan is 2025 114.83 % . FCF Conversion Rate (FCF/EBITDA) of Elan was 2024 153.90 % . It decreases by -25.38% lower compared to the previous year.

The Elan FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
125.78 JPY
Jan 1, 2019
71.64 JPY
Jan 1, 2020
128.62 JPY
Jan 1, 2021
106.42 JPY
Jan 1, 2022
59.26 JPY
Jan 1, 2023
62.94 JPY
Jan 1, 2024
153.90 JPY
Jan 1, 2025
114.83 JPY
The Elan FCF Conversion history
YEARFCF ConversionYoY
114.83 %-25.38%
153.90 %+144.52%
62.94 %+6.21%
59.26 %-44.32%
106.42 %-17.26%
128.62 %+79.55%
71.64 %-43.05%
125.78 %+239.65%
37.03 %-47.12%
70.04 %-2.44%
71.79 %-25.43%
96.27 %—
Access this data via the Eulerpool API

Elan Stock analysis

What does Elan do? Elan Corp is an Irish pharmaceutical company specializing in the research, development, and marketing of medications for neurological and autoimmune diseases. The company was founded in 1969 under the name Athlone Laboratories and has since undergone significant changes in both its business fields and its name. In 1996, the company was renamed Elan Corporation, a name it still holds today. At that time, the company primarily focused on researching and developing medications for Alzheimer's and Parkinson's diseases. However, in the following years, the company shifted its focus more towards treating autoimmune diseases such as multiple sclerosis and Crohn's disease. Elan Corp's business model is based on the development of medications through research and development as well as the acquisition of established therapeutics. One key component of the product portfolio is the medication Tysabri, which was developed in collaboration with Biogen Idec. It is used to treat multiple sclerosis patients and is one of Elan's top-selling medications, contributing significantly to the company's success. Elan Corp consists of three main business areas: 1. Biopharmaceuticals This division is responsible for the research and development of medications for neurological diseases such as Alzheimer's, Parkinson's, and multiple sclerosis. Some of the key products in this area, in addition to Tysabri, include Axona, a nutritional supplement to enhance cognitive function in Alzheimer's patients, and Zanaflex, which is used to treat muscle spasms in the majority of multiple sclerosis patients. 2. Neurology In this division, Elan focuses on the marketing and distribution of nerve and pain medications, as well as products for treating infections. Some of the key products in this area are Skelaxin, a muscle relaxant for pain and muscle spasms, and Biaxin, an antibiotic for treating infections. 3. Medical Technology Elan Corp's medical technology division specializes in the development and marketing of infusion pumps. The company primarily offers its products and services in the United States and Europe and holds a strong position in this market. Elan Corp is a company with a strong focus on research and development. Its key products are medications for treating neurological and autoimmune diseases, with Tysabri being the most well-known and successful. The company has undergone significant changes over the years and now focuses on developing medications for autoimmune diseases in the neurology field. With a strong emphasis on research and development, as well as the acquisition of established therapeutics, Elan Corp is an important player in the pharmaceutical industry and is expected to continue growing and succeeding in the future. Elan is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Elan stock

FCF Conversion Rate (FCF/EBITDA) of Elan is 114.83 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Elan changed from 153.90 % to 114.83 %, representing a -25.38% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Elan since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Elan with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — Elan

All Key Metrics — Elan